BRTX logo

BRTX
BioRestorative Therapies Inc

3,804
Mkt Cap
$5.13M
Volume
289,749.00
52W High
$2.05
52W Low
$0.19
PE Ratio
-0.12
BRTX Fundamentals
Price
$0.1978
Prev Close
$0.2012
Open
$0.1972
50D MA
$0.2517
Beta
1.38
Avg. Volume
1.35M
EPS (Annual)
-$1.58
P/B
5.21
Rev/Employee
$25,692.86
$7.77
Loading...
Loading...
News
all
press releases
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17h ago
News Placeholder
More News
News Placeholder
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +93.35% and +16.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of +60.00% and +2.94%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing
Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks·15d ago
News Placeholder
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading 5.7% Higher - Here's Why
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading 5.7% Higher - What's Next...
MarketBeat·24d ago
News Placeholder
BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Down 4.5% - Here's What Happened
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Down 4.5% - What's Next...
MarketBeat·2mo ago
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +13.51% and -90.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates
ABSCI CORP (ABSI) delivered earnings and revenue surprises of -40.24% and -82.15%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -58.33% and +4.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -17.02% and -72.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
<
1
2
...
>

Latest BRTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.